NCT02052661View on ClinicalTrials.gov

This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa

PHASE4CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

February 18, 2014

Primary Completion Date

September 23, 2014

Study Completion Date

September 23, 2014

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B Kinder

Single dose administered intramuscularly in deltoid region of non-dominant arm.

Trial Locations (11)

13055

GSK Investigational Site, Berlin

24534

GSK Investigational Site, Neumünster

24937

GSK Investigational Site, Flensburg

32584

GSK Investigational Site, Löhne

47574

GSK Investigational Site, Goch

67227

GSK Investigational Site, Frankenthal

77694

GSK Investigational Site, Kehl

78532

GSK Investigational Site, Tuttlingen

95463

GSK Investigational Site, Bindlach

04178

GSK Investigational Site, Leipzig

01445

GSK Investigational Site, Radebeul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02052661 - This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa | Biotech Hunter | Biotech Hunter